The human microbiome comprises trillions of bacteria, viruses, fungi, and other microorganisms that inhabit various sites of the body, notably the gut, skin, mouth, and respiratory tract. This complex ecosystem functions as an integral organ, influencing digestion, metabolism, protection against pathogens, and, crucially, the development and regulation of the immune system. Over the past decade, a growing body of research has established that the composition and diversity of the microbiome are dynamic, shifting in response to diet, environment, medications, and lifestyle. One of the most compelling areas of investigation concerns the relationship between microbiome diversity and the risk of autoimmune diseases. Autoimmune conditions, which affect an estimated 5–10% of the global population, arise when the immune system loses tolerance to self-antigens and launches an attack against the body’s own tissues. Emerging evidence suggests that a loss of microbial richness and variety may be a key environmental trigger or contributor to this breakdown of self-tolerance. This article explores how changes in microbiome diversity influence autoimmune disease risk, the underlying mechanisms, the evidence for specific conditions, and the potential for microbiome-directed interventions in prevention and treatment.

The Microbiome: Composition, Diversity, and Functions

The human gut microbiome is the most extensively studied microbial community. In a healthy adult, the gut harbors hundreds to thousands of bacterial species, with the dominant phyla being Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria. Diversity in this context refers to both the number of different species (richness) and their relative abundance (evenness). A high-diversity microbiome is generally considered a hallmark of health, as it provides functional redundancy—meaning that if one species is lost, others can perform similar roles. This redundancy supports resilience against perturbations such as dietary changes or antibiotic exposure.

Beyond the gut, microbiomes exist on the skin, in the oral cavity, in the lungs, and in the urogenital tract. Each site has a distinct microbial signature shaped by local environmental conditions. The skin microbiome, for example, includes Staphylococcus, Propionibacterium, and Corynebacterium species and plays a role in barrier function and immune education. The oral microbiome is among the most diverse, with over 700 species commonly found, and it influences systemic health through connections to the gut and the immune system.

The microbiome’s influence on the immune system is multifaceted. Microbial components such as lipopolysaccharide (LPS), peptidoglycan, and flagellin are recognized by pattern recognition receptors (PRRs) on immune cells, triggering innate responses. Short-chain fatty acids (SCFAs) produced by bacterial fermentation of dietary fiber—including acetate, propionate, and butyrate—regulate T-cell differentiation, promote regulatory T-cell (Treg) expansion, and enhance intestinal barrier integrity. These mechanisms are essential for maintaining immune homeostasis and preventing inflammatory responses against harmless antigens, including self-tissues.

Autoimmune Disease Mechanisms: Loss of Tolerance and Inflammatory Cascades

Autoimmune diseases are characterized by a breakdown of self-tolerance, leading to the activation of autoreactive T and B cells. The exact triggers are often unclear but are believed to involve a combination of genetic susceptibility (e.g., certain HLA alleles) and environmental factors. The microbiome is increasingly recognized as a major environmental variable that can either promote or protect against autoimmunity.

In a healthy state, the immune system maintains tolerance through several checkpoints. Central tolerance occurs in the thymus and bone marrow, where self-reactive lymphocytes are eliminated. Peripheral tolerance mechanisms include anergy, deletion, and suppression by Tregs. The microbiome influences peripheral tolerance by shaping the pool of Tregs. For instance, specific strains of Clostridium clusters IV and XIVa induce colonic Tregs, while Bacteroides fragilis promotes anti-inflammatory responses via polysaccharide A (PSA). When microbial diversity declines, these protective signals may be weakened, tipping the balance toward inflammation and autoimmunity.

Inflammatory cascades in autoimmune diseases often involve Th1, Th17, and Th2 pathways, depending on the condition. Reduced microbiome diversity has been associated with an expansion of pro-inflammatory bacteria (e.g., certain Prevotella species in rheumatoid arthritis) and a loss of anti-inflammatory species (e.g., Faecalibacterium prausnitzii in inflammatory bowel disease). These shifts can alter the production of cytokines, chemokines, and other mediators that drive tissue-specific inflammation.

How Microbiome Diversity Influences Autoimmune Risk: Key Mechanisms

1. Epithelial Barrier Integrity

The intestinal epithelial lining serves as a physical and immunological barrier preventing microbial translocation. A diverse microbiome supports barrier function by promoting mucus production, tight junction expression, and secretion of antimicrobial peptides. SCFAs, particularly butyrate, strengthen the epithelial barrier by inducing mucin genes and enhancing tight junction assembly. When diversity is low, SCFA production falls, and barrier permeability increases—a condition known as “leaky gut.” This allows bacterial components to enter the lamina propria and systemic circulation, activating immune cells and potentially triggering autoimmunity. Elevated intestinal permeability has been documented in individuals with type 1 diabetes, multiple sclerosis, and systemic lupus erythematosus.

2. Immune Education and Treg Induction

A high-diversity microbiome presents a wide array of antigens and metabolites that train the immune system to distinguish self from non-self. Specific bacteria drive the differentiation of Tregs, which suppress autoreactive T cells. For example, Bifidobacterium infantis and Lactobacillus rhamnosus have been shown to increase Treg frequency in animal models. Conversely, a low-diversity microbiome may lack the microbial signals necessary to maintain a robust Treg pool, increasing the risk of self-reactivity. Studies in germ-free mice reveal that these animals have profoundly underdeveloped immune systems with fewer Tregs and heightened susceptibility to experimental autoimmune encephalomyelitis (a model of multiple sclerosis). Colonizing these mice with a complex microbiome restores Treg numbers and reduces disease severity.

3. Molecular Mimicry and Cross-Reactivity

Some microbial proteins share sequence or structural similarity with human self-antigens. When the immune system mounts a response against such microbial epitopes, cross-reactive T or B cells may also attack host tissues. For instance, in rheumatic heart disease, antibodies against group A Streptococcus M protein cross-react with cardiac myosin. In the context of microbiome diversity, a broader microbial repertoire increases the chance of exposure to mimicry-inducing organisms, which might seem contradictory to protection. However, diversity also enhances immune regulation that can keep such cross-reactive responses in check. The net effect may depend on the balance between pro-inflammatory and regulatory signals—something that a rich, balanced microbiome promotes.

4. Metabolite-Mediated Regulation

Beyond SCFAs, the microbiome produces a variety of metabolites that influence immune function. Secondary bile acids, for example, are converted from primary bile acids by gut bacteria and act on nuclear receptors such as FXR and TGR5 to modulate inflammation. Tryptophan metabolites like indole and kynurenine activate the aryl hydrocarbon receptor (AhR) on innate lymphoid cells and T cells, promoting IL-22 production and barrier repair. A diverse microbiome produces a broader spectrum of these immunomodulatory molecules, supporting a resilient, anti-inflammatory immune environment. Reduced diversity limits this metabolic output, potentially skewing the immune system toward a pro-inflammatory state.

Evidence from Specific Autoimmune Diseases

Rheumatoid Arthritis (RA)

Rheumatoid arthritis is a chronic inflammatory joint disease with a known genetic component (HLA-DRB1 shared epitope) but also significant environmental influences. Multiple studies using 16S rRNA sequencing have found that the gut microbiome of RA patients shows reduced diversity compared to healthy controls. Notably, levels of Faecalibacterium and Bifidobacterium are consistently lower, while Prevotella copri is often overrepresented. In a landmark study by Scher et al. (2013), new-onset RA patients harbored an expansion of Prevotella species that correlated with disease activity. The oral microbiome is also altered in RA, with Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans implicated through citrullination of host proteins, which may break tolerance to self-antigens. These findings suggest that restoring microbial diversity—particularly by increasing butyrate-producing bacteria—could help re-establish immune tolerance in RA.

Multiple Sclerosis (MS)

Multiple sclerosis is a demyelinating autoimmune disease of the central nervous system. Gut microbiome studies in MS patients have reported decreased abundances of Prevotella and Bacteroides and increased Akkermansia and Methanobrevibacter compared to controls. One study demonstrated that the microbiomes of MS patients had lower overall diversity and were enriched in pro-inflammatory species such as Pseudomonas and Mycoplana. Importantly, fecal microbiota transplantation (FMT) from healthy donors into MS patients has shown preliminary clinical benefits, including reduced relapse rates and improved neurological function in small trials. Experimental models further support the causal role of the microbiome: germ-free mice colonized with MS-patient microbiota develop more severe experimental autoimmune encephalomyelitis than those colonized with healthy microbiota.

Type 1 Diabetes (T1D)

Type 1 diabetes results from autoimmune destruction of pancreatic beta cells. The incidence of T1D has risen sharply in Western countries, implicating environmental factors. Studies of children at risk for T1D have revealed that a decline in gut microbiome diversity precedes seroconversion to autoantibody positivity. The BABYDIET study found that infants who later developed T1D had reduced abundances of Bifidobacterium and Lactobacillus and an increase in Bacteroides compared to those who remained healthy. Butyrate-producing species such as Faecalibacterium prausnitzii are also depleted in T1D cases. Dietary interventions that increase fiber and fermentable prebiotics have been shown to preserve beta-cell function in non-obese diabetic (NOD) mice, highlighting the potential for early-life microbiome modulation in T1D prevention.

Inflammatory Bowel Disease (IBD)

While IBD (Crohn’s disease and ulcerative colitis) is sometimes classified separately from classic autoimmune diseases, it involves immune-mediated inflammation of the gastrointestinal tract and is strongly linked to microbiome dysbiosis. Numerous studies show that IBD patients have significantly reduced microbial diversity, with a loss of Firmicutes (especially Faecalibacterium prausnitzii) and an expansion of Proteobacteria (e.g., Escherichia coli). Reduced diversity correlates with disease severity and poor response to therapy. Restoration of diversity through exclusive enteral nutrition, FMT, or probiotics is an active area of research. The success of FMT in treating Clostridioides difficile infection has spurred interest in applying similar approaches to IBD, though results have been mixed due to the complexity of the disease.

Factors That Drive Microbiome Diversity Loss and Autoimmune Risk

Antibiotic Use

Antibiotics are one of the most powerful disruptors of microbiome diversity. Broad-spectrum antibiotics can reduce species richness by 30–50% within days, and recovery is often incomplete. Epidemiological studies have repeatedly linked antibiotic exposure in early childhood—a critical developmental window—to increased risk of autoimmune diseases such as T1D, IBD, and juvenile idiopathic arthritis. For example, a large Swedish cohort study found that children treated with antibiotics in the first year of life had a significantly higher risk of developing T1D later. The presumed mechanism is that antibiotics eliminate key bacterial species responsible for immune education and Treg induction, leaving the host vulnerable to self-reactivity.

Western Diet

The typical Western diet—high in processed foods, saturated fats, refined sugars, and low in fiber—is a well-documented driver of microbiome diversity loss. Dietary fiber is the primary substrate for microbial fermentation, and its absence starves beneficial bacteria, leading to a collapse in diversity. Animal experiments show that switching mice from a high-fiber diet to a low-fiber diet rapidly reduces the abundance of fiber-degrading bacteria such as Bacteroides and Clostridium clusters. Human studies corroborate this: populations with traditional, fiber-rich diets (e.g., the Hadza hunter-gatherers) exhibit much higher gut microbiome diversity than Western populations. Low fiber intake has been associated with increased rates of IBD, RA, and MS in epidemiological surveys.

Cesarean Section and Formula Feeding

Mode of delivery profoundly affects the initial microbial colonization of infants. Vaginally delivered infants acquire a microbiome resembling their mother’s vaginal and gut flora, with high abundances of Lactobacillus, Prevotella, and Bifidobacterium. Cesarean-delivered infants, in contrast, are colonized by skin and environmental bacteria, leading to reduced overall diversity and a delayed acquisition of key commensals. This disruption has been linked to elevated risks of asthma, allergies, and possibly autoimmune diseases. Similarly, formula feeding (vs. breastfeeding) deprives infants of human milk oligosaccharides (HMOs) that selectively feed Bifidobacterium species, further limiting diversity.

Other Environmental Factors

Stress, sleep deprivation, and lack of physical activity have all been shown to alter the microbiome composition toward a less diverse state. Stress hormones like norepinephrine can directly affect bacterial growth, while chronic stress increases intestinal permeability and inflammation. Social and lifestyle factors that reduce exposure to microbes (such as urbanization, cleaner living conditions, and smaller family sizes) are also hypothesized to reduce microbiome diversity and contribute to the rising incidence of autoimmune diseases in industrialized nations—the so-called hygiene hypothesis.

Therapeutic Strategies to Restore Microbiome Diversity

Dietary Interventions

The most accessible and effective way to boost microbiome diversity is through diet. High-fiber, plant-rich diets such as the Mediterranean diet, the DASH diet, or traditional whole-food diets promote the growth of polysaccharide-degrading bacteria and increase SCFA production. Long-term dietary changes can significantly alter the microbiome within weeks. For autoimmune patients, a personalized approach may be needed, as some individuals with IBD or celiac disease may react to certain fibers. Nevertheless, general recommendations include consuming 25–30 g of fiber daily from a variety of sources (fruits, vegetables, legumes, whole grains) and including fermented foods like yogurt, kefir, kimchi, and sauerkraut, which provide live microbes.

Probiotics and Prebiotics

Probiotics are live microorganisms intended to confer a health benefit when administered in adequate amounts. While not all probiotics are effective for all conditions, specific strains have shown promise in autoimmune contexts. For instance, Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis have been studied in RA and MS, with some trials showing modest reductions in inflammation and symptom scores. Prebiotics are non-digestible fibers that selectively stimulate growth of beneficial bacteria. Inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS) have been shown to increase Bifidobacterium and Faecalibacterium abundances. Synbiotics (probiotics plus prebiotics) may offer synergistic benefits.

Fecal Microbiota Transplantation (FMT)

FMT involves transferring stool from a healthy donor into a recipient’s gastrointestinal tract to restore a disrupted microbiome. It is highly effective for recurrent C. difficile infection and is under investigation for autoimmune diseases. Small, open-label studies in MS and ulcerative colitis have reported improvements in disease activity and shifts toward a more diverse microbial profile. However, larger randomized controlled trials are needed to establish safety and efficacy. Standardization of donor screening, preparation protocols, and delivery methods remains a challenge. Regulatory considerations also vary by country, limiting widespread clinical use.

Live Biotherapeutic Products and Engineered Microbes

Advances in microbiome science have spurred the development of defined microbial consortia—known as live biotherapeutic products (LBPs)—designed to restore specific functions. For example, SER-287, a consortium of spore-forming Firmicutes, has been tested in ulcerative colitis. Engineered bacteria that produce anti-inflammatory molecules (e.g., IL-10, butyrate, or tregs-inducing antigens) are also being explored in preclinical models. These approaches offer the potential for targeted, reproducible interventions without the variability of FMT. However, they remain years away from routine clinical use.

Antibiotic Stewardship

Reducing unnecessary antibiotic use is a public health priority that also protects microbiome diversity. In clinical practice, antibiotics should be prescribed only when clearly indicated, and broad-spectrum agents should be avoided when narrow-spectrum alternatives are available. For patients who require antibiotics, concurrent use of probiotics may help mitigate diversity loss, though evidence is mixed. After antibiotic treatment, a high-fiber diet and possibly targeted prebiotics can accelerate recovery of the microbial community.

Challenges and Future Directions

While the link between microbiome diversity and autoimmune disease risk is compelling, several challenges remain. First, most human studies are cross-sectional, making it difficult to determine whether low diversity is a cause or a consequence of disease. Prospective cohort studies that follow individuals from early life through disease onset are needed to establish causality. Second, the microbiome is highly individualized, and responses to interventions vary widely. Personalized approaches based on microbiome profiling, host genetics, and immune status may be necessary. Third, mechanisms identified in animal models do not always translate to humans; for example, the protective effects of Prevotella in mice are at odds with its association with RA in some human studies.

Future research should focus on multi-omics integration—combining metagenomics, metabolomics, proteomics, and clinical data to identify predictive microbial signatures. Interventional trials with rigorous design (randomized, placebo-controlled, blinded) are essential to move from correlation to causation. Additionally, understanding the developmental windows when microbiome modulation is most effective (early life vs. adulthood) will inform prevention strategies.

Advances in culturing and gnotobiotic mouse models will allow mechanistic dissection of specific microbial strains and their products. Finally, ethical and regulatory frameworks must evolve to accommodate the use of live microbial therapies in autoimmune disease management.

Practical Recommendations for Maintaining a Healthy Microbiome

Based on current evidence, individuals can take steps to support microbiome diversity and potentially reduce autoimmune risk:

  • Eat a diverse, fiber-rich diet. Aim for 30+ different plant foods per week, including fruits, vegetables, legumes, nuts, seeds, and whole grains. This variety provides different fibers that feed distinct bacterial groups.
  • Incorporate fermented foods. Yogurt, kefir, kimchi, sauerkraut, kombucha, and miso supply live microbes that can transiently colonize the gut and promote diversity.
  • Limit processed foods and added sugars. These can promote the growth of pro-inflammatory bacteria at the expense of beneficial species.
  • Avoid unnecessary antibiotics. Take antibiotics only when prescribed for bacterial infections, and discuss with your healthcare provider whether a narrow-spectrum agent is appropriate.
  • Consider probiotics judiciously. Probiotics may be helpful after antibiotic use or for specific conditions, but talk to a doctor before starting, especially if you have an autoimmune disease or are immunocompromised.
  • Manage stress and prioritize sleep. Chronic stress and sleep deprivation can alter the gut microbiome; practices like meditation, exercise, and consistent sleep schedules may help.
  • Support research. Participation in clinical studies and microbiome research can accelerate the development of evidence-based interventions.

Conclusion

The emerging picture of microbiome diversity as a determinant of autoimmune disease risk represents a paradigm shift in our understanding of these complex conditions. A rich, balanced microbial community appears to be essential for training the immune system to tolerate self-antigens while maintaining the ability to fight pathogens. Loss of diversity—due to antibiotics, Western diet, cesarean section, or other environmental factors—can disrupt this education, leading to impaired barrier function, reduced Treg induction, altered metabolite signaling, and increased inflammatory potential. While many questions remain, the evidence across rheumatoid arthritis, multiple sclerosis, type 1 diabetes, and inflammatory bowel disease consistently points to low microbial diversity as a risk factor.

Excitingly, this field opens new avenues for prevention and treatment. Dietary modifications, probiotics, prebiotics, and interventions like fecal microbiota transplantation or live biotherapeutic products are being investigated to restore diversity and rebalance immune function. A personalized approach that accounts for an individual’s microbiome composition, genetics, and lifestyle will likely be most effective. As large-scale clinical trials and mechanistic studies progress, the hope is that microbiome-directed therapies will become integrated into the management of autoimmune diseases, offering patients a way to modulate risk and improve outcomes through the microbes they host.

For further reading, see the Nature Reviews Gastroenterology & Hepatology review on the role of the microbiota in inflammatory bowel disease, the Cell Host & Microbe article on microbiome signatures in type 1 diabetes, and the Annals of the Rheumatic Diseases study on gut microbiome and rheumatoid arthritis.